Next Article in Journal
If It Works, Don’t Touch It? A Cell-Based Approach to Studying 2-[18F]FDG Metabolism
Previous Article in Journal
Potential and Limits of Kidney Cells for Evaluation of Renal Excretion
Previous Article in Special Issue
Periorbital Nociception in a Progressive Multiple Sclerosis Mouse Model Is Dependent on TRPA1 Channel Activation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 14
Issue 9
10.3390/ph14090909
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve

by
Wendy Lajoso
†,
Grace Flower
†,
Vincenzo Giacco
†,
Anjuli Kaul
,
Circe La Mache
,
Andra Brăban
,
Angela Roxas
and
Nicola B. Hamilton
*
Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, Guy’s Campus, King’s College London, London SE1 1UL, UK
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2021, 14(9), 909; https://doi.org/10.3390/ph14090909
Submission received: 12 August 2021 / Revised: 2 September 2021 / Accepted: 3 September 2021 / Published: 9 September 2021
(This article belongs to the Special Issue TRPA1 Receptor as a Potential Therapeutic Target in Pain, Inflammation and Neurodegeneration)
Browse Figures
Versions Notes

Abstract

:
Oligodendrocytes produce myelin, which provides insulation to axons and speeds up neuronal transmission. In ischaemic conditions, myelin is damaged, resulting in mental and physical disabilities. Recent evidence suggests that oligodendrocyte damage during ischaemia can be mediated by Transient Receptor Potential Ankyrin-1 (TRPA1), whose activation raises intracellular Ca2+ concentrations and damages compact myelin. Here, we show that TRPA1 is constitutively active in oligodendrocytes and the optic nerve, as the specific TRPA1 antagonist, A-967079, decreases basal oligodendrocyte Ca2+ concentrations and increases the size of the compound action potential (CAP). Conversely, TRPA1 agonists reduce the size of the optic nerve CAP in an A-967079-sensitive manner. These results indicate that glial TRPA1 regulates neuronal excitability in the white matter under physiological as well as pathological conditions. Importantly, we find that inhibition of TRPA1 prevents loss of CAPs during oxygen and glucose deprivation (OGD) and improves the recovery. TRPA1 block was effective when applied before, during, or after OGD, indicating that the TRPA1-mediated damage is occurring during both ischaemia and recovery, but importantly, that therapeutic intervention is possible after the ischaemic insult. These results indicate that TRPA1 has an important role in the brain, and that its block may be effective in treating many white matter diseases.

Graphical Abstract

1. Introduction

Oligodendrocytes (OLs) wrap fatty myelin sheaths around axons to decrease the capacitance across the axonal membrane and increase the action potential speed. Myelin loss in diseases such as periventricular leukomalacia, leukodystrophies, multiple sclerosis, and stroke, leads to failure of neuronal transmission and thus mental and physical impairment. We have recently shown that cerebellar oligodendrocytes express transient receptor potential ankyrin-1 (TRPA1), whose activation during ischaemia causes excessive Ca2+ influx and myelin damage [1].
TRPA1 is one of a large family of tetrameric non-selective cation channels that are widely expressed in the grey and white matter of the CNS and are increasingly considered as potential therapeutic targets in brain disorders [2]. TRPA1 is sensitive to environmental irritants and endogenous electrophilic compounds that are formed during oxidative stress [3], which have been shown to evoke pain, cold, itch, and inflammation [4]. These compounds can activate TRPA1 by covalent modification of cysteine or lysine residues at distinct regions on its intracellular N-terminal; however, TRPA1 can also be activated by several other agonists that interact with regions within the pore. Like many TRP channels, TRPA1 is highly permeable to Na+ and Ca2+, which in turn can deregulate cell function and cause apoptosis. In cerebellar OLs, TRPA1 was shown to be activated during ischaemia via acidification of the cytosol [1]. However, until now we did not know whether OLs in other areas of the brain express functional TRPA1 and whether TRPA1 block is protective against loss of white matter function in ischaemia.
Here, we show by patch-clamping corpus callosum OLs, that they also respond to TRPA1 agonists by raising their intracellular Ca2+ concentrations ([Ca2+]i), and that TRPA1 inhibition with A-967079 (20 µM) reduces the resting [Ca2+]i. Furthermore, the TRPA1 antagonist also increases the amplitude of optic nerve compound action potential (CAP) recordings under normal physiological conditions and prevents a large proportion of the oxygen and glucose deprivation (OGD) -induced loss of action potential. This shows that TRPA1 may play a role in regulating neuronal excitability and TRPA1 inhibition may be a possible treatment for white matter damage in diseases where acute or chronic ischaemia has been implicated.

2. Results

2.1. Oligodendrocytes Express Tonically Active TRPA1

The corpus callosum (CC) is a white matter tract spanning across the two hemispheres that is often thinned or demyelinated as a result of local hypoperfusion occurring in periventricular leukomalacia or stroke victims [1]. Therefore, our first aim was to determine whether OLs in the CC also express functional TRPA1. To do this, we whole cell patch-clamped OLs identified at first by their morphology (light oval somata laid in lines within parallel axons) and then by their dye-filled morphology (n = 28, Figure 1a). Using the patch-pipette, the OLs were dye filled with the Ca2+ sensitive dye Fluo-8 (200 µM). This method ensures that the measured [Ca2+]i changes are in OLs only. As previously reported in cerebellar OLs [2], the TRPA1 agonists flufenamic acid (FFA, 100 µM) and carvacrol (2 mM), evoke a [Ca2+]i increase in OLs in the corpus callosum (P12-17; Figure 1b,d). However, while the patch pipette was present, the TRPA1 agonists AITC (500 µM) and polygodial (100 µM) did not evoke a calcium increase. When we repeated the experiments with the patch-pipette removed, a short while after loading the cell with the Ca2+ indicators, we then found that AITC and polygodial were able to activate TRPA1 (Figure 1c,d). This lack of response to the electrophilic, covalently binding TRPA1 agonists (AITC and polygodial, Table 1) during patch-clamping techniques has been found previously [3] and suggests that a necessary intracellular component may be washed out or chelated in these instances, thus modifying the availability of the agonist binding site. Importantly, application of the TRPA1 antagonists A-967079 (20 µM) or HC-030031 (100 µM), whose mechanisms of action do not involve the N-terminal, decreases the resting [Ca2+]i in both corpus callosum and cerebellar OLs, as it does in astrocytes [4], suggesting that TRPA1 in OLs is tonically active (Figure 1e) and regulates normal cell functions.

2.2. Tonic TRPA1 Activation Regulates the Compound Action Potential Amplitude in the Optic Nerve

White matter Ca2+ concentrations, and receptors that allow Ca2+ flux, have been suggested to regulate action potential propagation in disease [12,13,14,15,16]. As TRPA1 regulates intracellular Ca2+ concentrations in oligodendrocytes, we hypothesised that tonic TRPA1 activity may influence oligodendrocyte function in maintaining fast neuronal action potential propagation. We used the optic nerve to measure CAP amplitude as described previously ([15,17]; Figure 2a) because it is a heavily myelinated, easily accessible CNS white matter tract [13]. Interestingly, we discovered a modest regulation of CAP amplitude by tonic TRPA1 activity in the optic nerve as TRPA1 inhibition with A-967079 (20 µM) increased the amplitude by 12 ± 4% within 10 min (n = 9; Figure 2b,c). Conversely, the TRPA1 agonists AITC (500 µM; n = 8; Figure 2d,g), and polygodial (10 or 100 µM; n = 6–7; Figure 2e,f,h,i) reduced the CAP amplitude (n = 5–14; Figure 2j). The TRPA1 agonist-induced decrease in compound action potential amplitude was reduced in the presence of A-967079, which was preincubated for over 15 min to allow for the initial increase in CAP amplitude before application of the agonists (n = 5–14; Figure 2j). As optic nerves do not include neuronal somata, these results indicate glial TRPA1 regulates retinal ganglion cell CAP propagation in physiological conditions. Whether this is due to OL or astrocyte TRPA1 is yet to be determined.

2.3. TRPA1 Block Protects against Loss of the Compound Action Potential during OGD

In the past, CAP recordings have demonstrated that simulated ischaemia results in a reduction in action potential propagation, with only a partial recovery [14,15,18,19,20]. This reduction in CAP amplitude is thought to be mediated by Ca2+ influx through different channels; therefore, TRPA1 inhibition may protect against loss of CAPs during ischaemia. To simulate ischaemia we removed O2 and glucose for 30 min, and continually recorded the CAP during a recovery period of 30 min (Figure 3). The area under the curve of the CAP was measured throughout. To understand the time at which TRPA1 activation may cause the most damage, we applied A-967079 at different times during the experiment. Firstly, we preincubated A-967079 (20 µM) and administered it throughout the experiment and found it significantly reduced the loss of the CAP during ischaemia (Figure 3b, and Figure 4a,d; p = 0.02) and improved the recovery from 61 ± 3.7% to 89 ± 7.4% (Figure 4a,e; p = 7.5 × 10−5). As therapeutics are more often than not given either during or after the event rather than prophylactically, we applied A-967079 during either the ischaemic insult or only the recovery period (Figure 3c,d and Figure 4b–e). A-967079 application during the ischaemic insult or the recovery period alone resulted in an improved CAP recovery (77 ± 8%; p = 0.02 and 73.7 ± 4%; p = 0.05, respectively) suggesting that the TRPA1-mediated damage is occurring during both the ischaemic and recovery periods. These results suggest that TRPA1 activation during ischaemia is a major cause of white matter damage and that TRPA1 antagonists may be effective in treating white matter in the many diseases involving ischaemia.

3. Discussion

The presence of TRPA1 in glial cells is a new concept, but the evidence for functional TRPA1 in both astrocytes [4,21] and OLs is growing [2,22,23,24,25], reviewed in [26]. In astrocytes and OLs, TRPA1 activation and inhibition raises and decreases basal intracellular Ca2+ (and Mg2+) concentrations, respectively [2,21] (Figure 1e). Astrocyte TRPA1 regulates neuronal function [4,21], and TRPA1 knockout appears to modify the expression of myelinating proteins [22]. Here, we add to this evidence by showing that TRPA1 expression in OLs is conserved in other CNS brain areas, and that activation of TRPA1 in corpus callosum OLs generates a substantial Ca2+ influx. Despite this, we did not find a large TRPA1-mediated non-specific cation current (that would reverse at −10 to 0 mV) as you would expect when TRPA1 is activated in large numbers on the cells [27]. Instead, we saw a TRPA1-mediated decrease in potassium conductance indicating a TRPA1-mediated inhibition of potassium channels. This has already been shown to occur when TRPA1 is activated during ischaemia [2]. This suggests that the levels of TRPA1 in OLs are low, which may be why its expression is not picked up in bulk brain studies [28], but is in single cell sequencing [23] and in situ hybridisation experiments [2]. Interestingly, TRPA1 was not found in mouse optic nerves during qPCR experiments [29]. This discrepancy is hard to explain as the mouse ages and strain were similar to those used here (C57BL6; P7, P30-40 vs. P12-18 and P42-70 here). Nonetheless, our evidence clearly points to functional expression of TRPA1 in the mouse optic nerve, and we provide the first evidence for a role for glial TRPA1 in regulating neuronal transmission through the white matter. Although the focus of this paper was the expression of TRPA1 in OLs, the effect of TRPA1 on astrocytes and possibly oligodendrocyte progenitor cells may be equally important. Future investigations will aim to specifically assess oligodendrocyte TRPA1 activity through use of TRPA1-shRNA or conditional knockouts.
How TRPA1 activity decreases the size of the CAPs under physiological conditions has not been completely elucidated. We know that removing extracellular Ca2+ protects against loss of CAPs during ischaemia [14], suggesting that influx of Ca2+ through TRPA1 may diminish the CAP. However, we also know that TRPA1 decreases oligodendrocyte potassium permeability ([2], Giacco et al., unpublished), which would in turn decrease the CAP amplitude by decreasing glial cell potassium syphoning away from the periaxonal space [30,31]. How the CAP is affected by inhibited OL potassium conductance is dependent on the amount that this changes the perinodal potassium concentration. Changes of a few mM can depolarise axons and lead to an increased excitability, but large changes (>10 mM) can lead to conduction block [32,33]. In our model, it appears that tonic TRPA1 activation in normal physiological conditions is already limiting axon excitability, or causing conduction block of a small set of axons and increased TRPA1 activation with exogenously applied agonists that builds upon that phenomenon. Therefore, it appears that either perinodal potassium concentrations are already high enough to prevent action propagation in some axons, or that the OL depolarisation or Ca2+ influx through TRPA1 is decreasing the excitability of axons in another way. In support of the former, one action potential is thought to increase the perinodal K+ concentration by 1 mM [34], and this may increase quickly with successive action potentials if potassium syphoning is hindered.
As mentioned above, increased extracellular Ca2+ concentrations are correlated with the amount of white matter damage occurring during ischaemia [12,14,35], and a large proportion of the Ca2+-mediated damage has long been thought to be due to glutamate excitotoxicity driving Ca2+ influx through OL AMPA/KA [35,36,37,38] and NMDA [12,14,15,39,40,41,42] receptors. However, our recent work indicates that the majority of the Ca2+ influx into OLs during ischaemia is through TRPA1, which becomes activated when OLs acidify as a result of raised extracellular potassium concentrations occurring during ischaemia [2]. Optic nerves subjected to ischaemia for 1 hour have TRPA1-mediated myelin damage shown with electron microscopy [2]. In line with that, we find here that TRPA1 inhibition is beneficial at protecting against white matter damage when applied during, after, or throughout the ischaemic insult, suggesting that TRPA1 block may be used as a potential prophylactic therapy, or one to improve recovery after a stroke. It is important to add, however, that the CAP area never returned to its pre-ischaemic level. This residual loss of the CAP may be due to activation of glutamate receptors, or due to underlying damage to the axons [36], rather than OLs.
At present, there are a large number of patents for the use of TRPA1 antagonists in human pathologies. A-967079 was chosen here because it is commercially available, highly selective, more readily dissolved in aqueous solution than HC-030031, and can penetrate the nervous system at therapeutic concentrations when administered peripherally, by oral gavage and intraperitoneal injection [43]. This opens up possibilities for testing the effects of A-967079 in vivo in stroke models. However, initial evidence suggests that TRPA1 activation on capillaries may induce vasodilation of arterioles and protect against widespread damage during stroke [44,45]. These results were determined using a conditional endothelial cell TRPA1 knockout [46]. Nonetheless, the evidence of TRPA1-mediated pathology within the parenchyma is growing substantially and indicates that targeted TRPA1 knockout or block within the parenchyma will have major benefits and needs investigating further.

4. Materials and Methods

4.1. Animals

C57BL/6J mice of either sex were killed via schedule 1 (cervical dislocation) in accordance with the guidelines of the UK Animals (Scientific Procedures) Act 1986 and subsequent amendments. The protocols were approved by the Animal Welfare Ethical Review Body of Guy’s Campus, King’s College London (PPL number P7322191B, granted on 26 April 2019 and amended on 11 November 2019).

4.2. Brain Slice and Optic Nerve Preparation

Coronal brain slices (225 µm thick) were prepared from the brains of P12-P17 mice in ice-cold solution containing (mM) 124 NaCl, 26 NaHCO3, 1 NaH2PO4, 2.5 KCl, 2 MgCl2, 2 CaCl2, 10 glucose, bubbled with 95% O2/5% CO2, pH 7.4, as well as 1 mM Na-kynurenate to block glutamate receptors. Optic nerves were dissected from P42-P70 mice. Brain slices and optic nerves were then incubated at room temperature (21–24 °C) in the above solution until used in experiments.

4.3. Cell Identification and Electrophysiology

Oligodendrocytes were identified by their location and morphology. All cells were whole-cell clamped with pipettes with a series resistance of 8–35 MΩ. Electrode junction potentials were compensated, and cells were voltage-clamped at −74 mV.

4.4. External Solutions

Slices and optic nerves were superfused with bicarbonate-buffered solution containing (mM) 124 NaCl, 2.5 KCl, 26 NaHCO3, 1 NaH2PO4, 2 CaCl2, 1 MgCl2, 10 glucose, pH 7.4, bubbled with 95% O2 and 5% CO2. Applications of TRPA1 channel agonists and antagonists to brain slices were at room temperature. All CAP recording and OGD experiments were performed between 33 °C and 36 °C. Data were excluded if changes in temperature were observed during the experiment. Control and drug conditions were interleaved and the experimenter was blinded to the solution contents. To simulate ischaemia, we replaced external O2 with N2, and external glucose with 7 mM sucrose. The flow rate was approximately 4 mL/min into a 1.5 mL bath, giving a turnover rate of under 25 s.

4.5. Intracellular Solutions

Cells were whole-cell clamped with electrodes containing K-gluconate-based solution, comprising (mM) 130 K-gluconate, 2 NaCl, 0.5 CaCl2, 10 HEPES, 10 BAPTA, 2 NaATP, 0.5 Na2GTP, 2 MgCl, and 0.05 Alexa Fluor 594, and pH set to 7.15 with K-OH (all from Sigma-Aldrich, Germany). For Ca2+ imaging experiments, BAPTA was decreased to 0.01 mM and replaced with 10 mM phosphocreatine, CaCl2 was reduced to 10 µM, and 200 µM Fluo-4 or Fluo-8 was added to allow ratiometric imaging with the above Alexa Fluor.

4.6. Single Cell Ion Imaging

Fluo-8 and Alexa Fluor 594 were used in the internal solution to measure [Ca2+]i changes ratiometrically during experiments. Fluo-8 and Alexa Fluor 594 fluorescence were excited sequentially using a monochromator every 3 s at 488 ± 10 nm and 585 ± 10 nm, and emission was collected using a triband filter cube (DAPI/FITC/Texas Red, 69002, Chroma Technology Corporation, Bellow Falls, VT, USA). The mean ratio of intensities (excited at 488 nm/excited at 585 nm) before applying the TRPA1 agonist was 1.010 (n = 28).

4.7. Drug Application

Stock solutions of the following drugs were made up: Carvacrol (Sigma-Aldrich, Darmstadt, Germany) was diluted in 100% ethanol, HC 030031 (Tocris Bioscience, Bristol, UK), A-967079 (Boc Sciences, Shirley, NY, USA), flufenamic acid (Sigma-Aldrich, Darmstadt, Germany), polygodial (Tocris Bioscience, Bristol, UK), and AITC (Sigma-Aldrich, Darmstadt, Germany) were made up in 100% DMSO. For CAP experiments, DMSO and ethanol were also added to control solutions at the same concentrations and did not evoke any changes in the CAP amplitude at the concentrations used (≤0.1%). For the patch-clamping experiments, vehicle controls were tested on oligodendrocytes and did not evoke any changes at the concentrations used. Stocks were kept at −20 °C apart from carvacrol and AITC, which were made up fresh on each day of use. To minimise evaporation of carvacrol, lids were kept on until the solutions were used. The control and test experiments were interleaved, and for all CAP recordings, the experimenter was blinded to the contents of the solutions.

4.8. Compound Action Potential Recording

Optic nerves were isolated from P42-P70 mice, and CAP recorded using suction electrodes [13]. The optic nerve was stimulated using a suction electrode filled with extracellular solution, using 0.2 ms, 50–100 V pulses, at 1 Hz to produce as supramaximal a response as possible. Supramaximal stimulation (40% over the voltage producing the maximal amplitude of CAP) was constrained by a maximum stimulation voltage of 100 V. The CAP was recorded as a voltage using an Axon Axoclamp 2B amplifier, with the recording suction electrodes placed as far away from the stimulating electrode as possible to obtain a CAP waveform with three peaks, which denoted heavily myelinated axons (peak 1), normally myelinated axons (peak 2) and unmyelinated axons (peak 3; [9]). At the end of each experiment, TTX (500 nM) was applied to obtain the stimulus artefact in the absence of action potentials, which were subtracted from all the records obtained previously. The pre-stimulus baseline of the resulting traces was subtracted, then the traces were rectified (squared, then square rooted), and either the area of the CAP was calculated or the amplitude of the second peak was measured (see results).

4.9. Statistics

Data were mean ± s.e.m. p-values were from ANOVA tests (for normally distributed data) and Mann–Whitney U or Kruskal–Wallis tests (for non-normally distributed data). Normally distributed data were tested for equal variance (p < 0.05, unpaired F-test), and paired t-Tests were adjusted accordingly. p-values quoted in the text were from ANOVA tests unless otherwise stated. For multiple comparisons, p-values were corrected using the Holm–Bonferroni or Tukey’s test. Small sample sizes were often able to achieve statistical significance, so in those instances, power analysis of sample size was also measured for soma data and determined to be greater than 0.75. Data normality was assessed using Shapiro–Wilk tests. All statistical analysis was conducted using OriginLab or GraphPad Prism software.

5. Conclusions

We provided the first evidence that TRPA1 activation in the white matter suppresses axonal function in both health and disease. Whether depression of neuronal activity is important for normal brain function is not known, but our results strongly indicate that TRPA1 block may preserve white matter function during and after ischaemic episodes in the brain. In light of the evidence provided above, it will be important to dissect the role of TRPA1 expressed by the different cell types to enhance our understanding of how the CNS is affected by TRPA1 activity in the brain.

Author Contributions

Investigation, analysis, methodology, data curation, and project administration, W.L., G.F., V.G., A.K., C.L.M., A.B., A.R. and N.B.H.; conceptualisation, validation, visualisation and supervision, G.F., V.G. and N.B.H.; writing—original draft preparation, N.B.H.; writing—review and editing, G.F., V.G. and N.B.H.; funding acquisition, N.B.H. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a European Leukodystrophies Grant (ELA2017-015I4), Medical Research Council New Investigator Grant (MR/S003045/1), and King’s College London.

Institutional Review Board Statement

The study was conducted according to the guidelines of the UK Animals (Scientific Procedures) Act 1986 and subsequent amendments. The protocols were approved by the Animal Welfare Ethical Review Body of Guy’s Campus, King’s College London (PPL number P7322191B, granted on 26 April 2019 and amended on 11 November 2019).

Informed Consent Statement

Not applicable.

Data Availability Statement

Please contact the corresponding author to obtain the original data which, for the electrophysiology data, are in the form of abf files that can be read by free Clampfit Software (Molecular Devices). Imaging data are available as files composed by the MetaFluor Imaging Series that can be imported for analysis into ImageJ.

Acknowledgments

We thank Peter McNaughton for comments on the manuscript.

Conflicts of Interest

The authors declare that they have no competing interests.

References

  1. Yang, L.-L.; Huang, Y.-N.; Cui, Z.-T. Clinical features of acute corpus callosum infarction patients. Int. J. Clin. Exp. Pathol. 2014, 7, 5160–5164. [Google Scholar]
  2. Hamilton, N.B.; Kolodziejczyk, K.; Kougioumtzidou, E.; Attwell, D. Proton-gated Ca2+-permeable TRP channels damage myelin in conditions mimicking ischaemia. Nature 2016, 529, 523–527. [Google Scholar] [CrossRef] [Green Version]
  3. Kim, D.; Cavanaugh, E.J. Requirement of a soluble intracellular factor for activation of transient receptor potential A1 by pungent chemicals: Role of inorganic polyphosphates. J. Neurosci. 2007, 27, 6500–6509. [Google Scholar] [CrossRef] [Green Version]
  4. Shigetomi, E.; Tong, X.; Kwan, K.Y.; Corey, D.P.; Khakh, B.S. TRPA1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. Nat. Neurosci. 2012, 15, 70–80. [Google Scholar] [CrossRef] [Green Version]
  5. Meents, J.E.; Fischer, M.J.M.; McNaughton, P.A. Agonist-induced sensitisation of the irritant receptor ion channel TRPA1. J. Physiol. 2016, 594, 6643–6660. [Google Scholar] [CrossRef]
  6. Hu, H.; Tian, J.; Zhu, Y.; Wang, C.; Xiao, R.; Herz, J.M.; Wood, J.D.; Zhu, M.X. Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch. 2010, 459, 579–592. [Google Scholar] [CrossRef] [Green Version]
  7. Andrade, E.L.; Meotti, F.C.; Calixto, J.B. TRPA1 antagonists as potential analgesic drugs. Pharmacol. Ther. 2012, 133, 189–204. [Google Scholar] [CrossRef]
  8. Ton, H.T.; Phan, T.X.; Abramyan, A.M.; Shi, L.; Ahern, G.P. Identification of a putative binding site critical for general anesthetic activation of TRPA1. Proc. Natl. Acad. Sci. USA 2017, 114, 3762–3767. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Mathie, K.; Lainer, J.; Spreng, S.; Dawid, C.; Andersson, D.A.; Bevan, S.; Hofmann, T. Structure-Pungency Relationships and TRP Channel Activation of Drimane Sesquiterpenes in Tasmanian Pepper (Tasmannia lanceolata). J. Agric. Food Chem. 2017, 65, 5700–5712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Hinman, A.; Chuang, H.-H.; Bautista, D.M.; Julius, D. TRP channel activation by reversible covalent modification. Proc. Natl. Acad. Sci. USA 2006, 103, 19564–19568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Takaya, J.; Mio, K.; Shiraishi, T.; Kurokawa, T.; Otsuka, S.; Mori, Y.; Uesugi, M. A Potent and Site-Selective Agonist of TRPA1. J. Am. Chem. Soc. 2015, 137, 15859–15864. [Google Scholar] [CrossRef] [Green Version]
  12. Micu, I.; Jiang, Q.; Coderre, E.; Ridsdale, A.; Zhang, L.; Woulfe, J.; Yin, X.; Trapp, B.D.; McRory, J.E.; Rehak, R.; et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006, 439, 988–992. [Google Scholar] [CrossRef]
  13. Stys, P.K.; Ransom, B.R.; Waxman, S.G. Compound action potential of nerve recorded by suction electrode: A theoretical and experimental analysis. Brain Res. 1991, 546, 18–32. [Google Scholar] [CrossRef]
  14. Stys, P.K.; Ransom, B.R.; Waxman, S.G.; Davis, P.K. Role of extracellular calcium in anoxic injury of mammalian central white matter. Proc. Natl. Acad. Sci. USA 1990, 87, 4212–4216. [Google Scholar] [CrossRef] [Green Version]
  15. Bakiri, Y.; Hamilton, N.B.; Káradóttir, R.; Attwell, D. Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter. Glia 2008, 56, 233–240. [Google Scholar] [CrossRef] [Green Version]
  16. Baltan, S. Age-specific localization of NMDA receptors on oligodendrocytes dictates axon function recovery after ischemia. Neuropharmacology 2016, 110, 626–632. [Google Scholar] [CrossRef] [Green Version]
  17. Bolton, S.; Butt, A.M. The optic nerve: A model for axon-glial interactions. J. Pharmacol. Toxicol. Methods 2005, 51, 221–233. [Google Scholar] [CrossRef]
  18. Bastian, C.; Brunet, S.; Baltan, S. Ex vivo studies of optic nerve axon electrophysiology. Methods Mol. Biol. 2020, 2143, 169–177. [Google Scholar] [CrossRef] [PubMed]
  19. Dong, C.-J.; Hare, W.A. Contribution to ischemic injury of rat optic nerves by intracellular sodium overload. Doc. Ophthalmol. 2005, 110, 15–23. [Google Scholar] [CrossRef] [PubMed]
  20. Hamner, M.A.; Ye, Z.; Lee, R.V.; Colman, J.R.; Le, T.; Gong, D.C.; Ransom, B.R.; Weinstein, J.R. Ischemic preconditioning in white matter: Magnitude and mechanism. J. Neurosci. 2015, 35, 15599–15611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Shigetomi, E.; Jackson-Weaver, O.; Huckstepp, R.T.; O’Dell, T.J.; Khakh, B.S. TRPA1 channels are regulators of astrocyte basal calcium levels and long-term potentiation via constitutive D-serine release. J. Neurosci. 2013, 33, 10143–10153. [Google Scholar] [CrossRef]
  22. Lee, K.-I.; Lin, H.-C.; Lee, H.-T.; Tsai, F.-C.; Lee, T.-S. Loss of transient receptor potential ankyrin 1 channel deregulates emotion, learning and memory, cognition, and social behavior in mice. Mol. Neurobiol. 2017, 54, 3606–3617. [Google Scholar] [CrossRef] [PubMed]
  23. Marques, S.; Zeisel, A.; Codeluppi, S.; van Bruggen, D.; Mendanha Falcão, A.; Xiao, L.; Li, H.; Häring, M.; Hochgerner, H.; Romanov, R.A.; et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 2016, 352, 1326–1329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Kriszta, G.; Nemes, B.; Sándor, Z.; Ács, P.; Komoly, S.; Berente, Z.; Bölcskei, K.; Pintér, E. Investigation of Cuprizone-Induced Demyelination in mGFAP-Driven Conditional Transient Receptor Potential Ankyrin 1 (TRPA1) Receptor Knockout Mice. Cells 2019, 9, 81. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Bölcskei, K.; Kriszta, G.; Sághy, É.; Payrits, M.; Sipos, É.; Vranesics, A.; Berente, Z.; Ábrahám, H.; Ács, P.; Komoly, S.; et al. Behavioural alterations and morphological changes are attenuated by the lack of TRPA1 receptors in the cuprizone-induced demyelination model in mice. J. Neuroimmunol. 2018, 320, 1–10. [Google Scholar] [CrossRef] [PubMed]
  26. Cornillot, M.; Giacco, V.; Hamilton, N.B. The role of TRP channels in white matter function and ischaemia. Neurosci. Lett. 2019, 690, 202–209. [Google Scholar] [CrossRef] [Green Version]
  27. Ye, W.; Tu, Y.-H.; Cooper, A.J.; Zhang, Z.; Katritch, V.; Liman, E.R. Activation Stoichiometry and Pore Architecture of TRPA1 Probed with Channel Concatemers. Sci. Rep. 2018, 8, 17104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Cahoy, J.D.; Emery, B.; Kaushal, A.; Foo, L.C.; Zamanian, J.L.; Christopherson, K.S.; Xing, Y.; Lubischer, J.L.; Krieg, P.A.; Krupenko, S.A.; et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J. Neurosci. 2008, 28, 264–278. [Google Scholar] [CrossRef] [Green Version]
  29. Papanikolaou, M.; Lewis, A.; Butt, A.M. Store-operated calcium entry is essential for glial calcium signalling in CNS white matter. Brain Struct. Funct. 2017, 222, 2993–3005. [Google Scholar] [CrossRef] [Green Version]
  30. Djukic, B.; Casper, K.B.; Philpot, B.D.; Chin, L.-S.; McCarthy, K.D. Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. J. Neurosci. 2007, 27, 11354–11365. [Google Scholar] [CrossRef]
  31. Larson, V.A.; Mironova, Y.; Vanderpool, K.G.; Waisman, A.; Rash, J.E.; Agarwal, A.; Bergles, D.E. Oligodendrocytes control potassium accumulation in white matter and seizure susceptibility. Elife 2018, 7, e34829. [Google Scholar] [CrossRef]
  32. Kofuji, P.; Newman, E.A. Potassium buffering in the central nervous system. Neuroscience 2004, 129, 1045–1056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Rash, J.E. Molecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: Pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system. Neuroscience 2010, 168, 982–1008. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Ransom, C.B.; Ransom, B.R.; Sontheimer, H. Activity-dependent extracellular K+ accumulation in rat optic nerve: The role of glial and axonal Na+ pumps. J. Physiol. 2000, 522, 427–442. [Google Scholar] [CrossRef] [PubMed]
  35. Salter, M.G.; Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005, 438, 1167–1171. [Google Scholar] [CrossRef]
  36. Tekkök, S.B.; Goldberg, M.P. Ampa/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J. Neurosci. 2001, 21, 4237–4248. [Google Scholar] [CrossRef] [Green Version]
  37. McCarran, W.J.; Goldberg, M.P. White matter axon vulnerability to AMPA/kainate receptor-mediated ischemic injury is developmentally regulated. J. Neurosci. 2007, 27, 4220–4229. [Google Scholar] [CrossRef]
  38. Tekkök, S.B.; Ye, Z.; Ransom, B.R. Excitotoxic mechanisms of ischemic injury in myelinated white matter. J. Cereb. Blood Flow Metab. 2007, 27, 1540–1552. [Google Scholar] [CrossRef] [Green Version]
  39. Follett, P.L.; Rosenberg, P.A.; Volpe, J.J.; Jensen, F.E. NBQX attenuates excitotoxic injury in developing white matter. J. Neurosci. 2000, 20, 9235–9241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Manning, S.M.; Talos, D.M.; Zhou, C.; Selip, D.B.; Park, H.-K.; Park, C.-J.; Volpe, J.J.; Jensen, F.E. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J. Neurosci. 2008, 28, 6670–6678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Yang, X.; Hamner, M.A.; Brown, A.M.; Evans, R.D.; Ye, Z.-C.; Chen, S.; Ransom, B.R. Novel hypoglycemic injury mechanism: N-methyl-D-aspartate receptor-mediated white matter damage. Ann. Neurol. 2014, 75, 492–507. [Google Scholar] [CrossRef]
  42. Káradóttir, R.; Cavelier, P.; Bergersen, L.H.; Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005, 438, 1162–1166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Chen, J.; Joshi, S.K.; DiDomenico, S.; Perner, R.J.; Mikusa, J.P.; Gauvin, D.M.; Segreti, J.A.; Han, P.; Zhang, X.-F.; Niforatos, W.; et al. Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain 2011, 152, 1165–1172. [Google Scholar] [CrossRef] [PubMed]
  44. Earley, S. TRPA1 channels in the vasculature. Br. J. Pharmacol. 2012, 167, 13–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Pires, P.W.; Earley, S. Neuroprotective effects of TRPA1 channels in the cerebral endothelium following ischemic stroke. Elife 2018, 7, e35316. [Google Scholar] [CrossRef]
  46. Sullivan, M.N.; Gonzales, A.L.; Pires, P.W.; Bruhl, A.; Leo, M.D.; Li, W.; Oulidi, A.; Boop, F.A.; Feng, Y.; Jaggar, J.H.; et al. Localized TRPA1 channel Ca2+ signals stimulated by reactive oxygen species promote cerebral artery dilation. Sci. Signal. 2015, 8, ra2. [Google Scholar] [CrossRef] [Green Version]
Pharmaceuticals 14 00909 g001 550
Figure 1. Corpus callosum oligodendrocytes express TRPA1. (a) High magnification of a whole-cell patch clamped OL in corpus callosum (CC) with Alexa dye in the soma and processes. (b) Representative Δ [Ca2+]i trace responses to TRPA1 agonists with the patch-pipette remaining: FFA 100 µM (n = 6); carvacrol 2mM (n = 8); 500 µM AITC (n = 4); polygodial 100 µM (n = 6). (c) Δ [Ca2+]i to TRPA1 agonists with the patch-pipette removed: AITC 500 µM (n = 5); polygodial 100 µM (n = 6). (d) Mean ± SEM maximum Δ [Ca2+]i in response to TRPA1 agonists (p-values compared with and without patch pipette, one-way ANOVA test with Holm-Bonferroni correction for multiple comparisons). (e) The graph shows a decrease in resting [Ca2+]i that occurs in the presence of TRPA1 antagonists: A-967079 20 µM in CC Ols and HC-030031 100 µM in cerebellar (Cer) OLs.
Figure 1. Corpus callosum oligodendrocytes express TRPA1. (a) High magnification of a whole-cell patch clamped OL in corpus callosum (CC) with Alexa dye in the soma and processes. (b) Representative Δ [Ca2+]i trace responses to TRPA1 agonists with the patch-pipette remaining: FFA 100 µM (n = 6); carvacrol 2mM (n = 8); 500 µM AITC (n = 4); polygodial 100 µM (n = 6). (c) Δ [Ca2+]i to TRPA1 agonists with the patch-pipette removed: AITC 500 µM (n = 5); polygodial 100 µM (n = 6). (d) Mean ± SEM maximum Δ [Ca2+]i in response to TRPA1 agonists (p-values compared with and without patch pipette, one-way ANOVA test with Holm-Bonferroni correction for multiple comparisons). (e) The graph shows a decrease in resting [Ca2+]i that occurs in the presence of TRPA1 antagonists: A-967079 20 µM in CC Ols and HC-030031 100 µM in cerebellar (Cer) OLs.
Pharmaceuticals 14 00909 g001
Pharmaceuticals 14 00909 g002 550
Figure 2. TRPA1 agonist and antagonist effects on optic nerve compound action potential amplitude. (a) Compound action potentials (CAPs) were measured in young adult optic nerves (P42–P70). (b) A-967079 (A96, 10 μM) block of TRPA1 increases the CAP amplitude (black trace at start; with time this increases (grey traces), and the red trace is the final trace). The arrows indicate the direction of change in CAP measurements with time. (c) Mean (± SEM) CAP amplitude increases after application of A-967079 (10 μM; n = 7) compared to vehicle (DMSO; n = 12), and decreases after TRPA1 agonist application: AITC (500 μM, (d,g,j), n =8); and polygodial (10 μM, (e,h,j), n = 7; and 100 μM, (f,i,j), n = 6). TRPA1–evoked decreases can be significantly inhibited by over 15 min of preincubation with A-967079 (20 μM, g–j). (j) Bar graph showing the mean (± SEM) changes in CAP amplitude (each n is depicted as a diamond data point) after application of agonists and antagonists for 10 min. p-values are from multiple comparisons using a one-way ANOVA with Holm–Bonferroni correction.
Figure 2. TRPA1 agonist and antagonist effects on optic nerve compound action potential amplitude. (a) Compound action potentials (CAPs) were measured in young adult optic nerves (P42–P70). (b) A-967079 (A96, 10 μM) block of TRPA1 increases the CAP amplitude (black trace at start; with time this increases (grey traces), and the red trace is the final trace). The arrows indicate the direction of change in CAP measurements with time. (c) Mean (± SEM) CAP amplitude increases after application of A-967079 (10 μM; n = 7) compared to vehicle (DMSO; n = 12), and decreases after TRPA1 agonist application: AITC (500 μM, (d,g,j), n =8); and polygodial (10 μM, (e,h,j), n = 7; and 100 μM, (f,i,j), n = 6). TRPA1–evoked decreases can be significantly inhibited by over 15 min of preincubation with A-967079 (20 μM, g–j). (j) Bar graph showing the mean (± SEM) changes in CAP amplitude (each n is depicted as a diamond data point) after application of agonists and antagonists for 10 min. p-values are from multiple comparisons using a one-way ANOVA with Holm–Bonferroni correction.
Pharmaceuticals 14 00909 g002
Pharmaceuticals 14 00909 g003 550
Figure 3. Ischaemia-evoked changes in optic nerve compound action potential (CAP). (a) Top row, traces from the left are: CAP in control solution, after 30 min ischemia, after 30 min recovery to control solution, after application of 500 nM TTX to record the stimulus artefact. Row b shows the same traces after the stimulus artefact has been removed from the traces. (b–d) Artefact subtracted responses with A-967079 (20 μM) preincubated and added throughout the experiment (b) during ischaemia only (c) or during the recovery only (d).
Figure 3. Ischaemia-evoked changes in optic nerve compound action potential (CAP). (a) Top row, traces from the left are: CAP in control solution, after 30 min ischemia, after 30 min recovery to control solution, after application of 500 nM TTX to record the stimulus artefact. Row b shows the same traces after the stimulus artefact has been removed from the traces. (b–d) Artefact subtracted responses with A-967079 (20 μM) preincubated and added throughout the experiment (b) during ischaemia only (c) or during the recovery only (d).
Pharmaceuticals 14 00909 g003
Pharmaceuticals 14 00909 g004 550
Figure 4. Ischaemia-evoked changes in optic nerve compound action potential (CAP) are reduced by TRPA1 block with A-967079. (a) Normalised area of CAP before, during, and after ischaemia, simulated by removing oxygen and glucose and replacing them with nitrogen and sucrose, showing how preincubation of the TRPA1 antagonist (A-967079, 20 μM) can prevent the loss of the CAP during ischaemia and improve the recovery after replacement of oxygen and glucose. Application of A-967079 during ischaemia (b) or during recovery (c) only is also protective. (d) Normalised CAP area after 30 min in OGD or after 30 min recovery (e). p-values in (d) are from Mann–Whitney tests with Holm–Bonferroni correction for multiple comparisons. p-values in (e) are from a one-way ANOVA with Holm–Bonferroni correction for multiple comparisons.
Figure 4. Ischaemia-evoked changes in optic nerve compound action potential (CAP) are reduced by TRPA1 block with A-967079. (a) Normalised area of CAP before, during, and after ischaemia, simulated by removing oxygen and glucose and replacing them with nitrogen and sucrose, showing how preincubation of the TRPA1 antagonist (A-967079, 20 μM) can prevent the loss of the CAP during ischaemia and improve the recovery after replacement of oxygen and glucose. Application of A-967079 during ischaemia (b) or during recovery (c) only is also protective. (d) Normalised CAP area after 30 min in OGD or after 30 min recovery (e). p-values in (d) are from Mann–Whitney tests with Holm–Bonferroni correction for multiple comparisons. p-values in (e) are from a one-way ANOVA with Holm–Bonferroni correction for multiple comparisons.
Pharmaceuticals 14 00909 g004
Table
Table 1. TRPA1 agonist binding sites.
Table 1. TRPA1 agonist binding sites.
TRPA1 AgonistCovalent Binding
(N-Terminal)		Non-Covalent Binding
Carvacrol-Unknown other site [5]
Flufenamic Acid (FFA)-Unknown other site [6]
Menthol-TM5 [7]
Isoflurane, propofol-TM5, TM6 and the pore helix 1 [8]
A-967079 (antagonist)-TM5, TM6 and the pore helix 1 [8]
Polygodial (PolyG)Lys residues [9]-
AITC (mustard oil)Cys and Lys residues [10]-
CinnemaldehydeCys and Lys residues [10]-
JT010Cys621 only [11]-
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lajoso, W.; Flower, G.; Giacco, V.; Kaul, A.; La Mache, C.; Brăban, A.; Roxas, A.; Hamilton, N.B. Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve. Pharmaceuticals 2021, 14, 909. https://doi.org/10.3390/ph14090909

AMA Style

Lajoso W, Flower G, Giacco V, Kaul A, La Mache C, Brăban A, Roxas A, Hamilton NB. Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve. Pharmaceuticals. 2021; 14(9):909. https://doi.org/10.3390/ph14090909

Chicago/Turabian Style

Lajoso, Wendy, Grace Flower, Vincenzo Giacco, Anjuli Kaul, Circe La Mache, Andra Brăban, Angela Roxas, and Nicola B. Hamilton. 2021. "Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve" Pharmaceuticals 14, no. 9: 909. https://doi.org/10.3390/ph14090909

APA Style

Lajoso, W., Flower, G., Giacco, V., Kaul, A., La Mache, C., Brăban, A., Roxas, A., & Hamilton, N. B. (2021). Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve. Pharmaceuticals, 14(9), 909. https://doi.org/10.3390/ph14090909

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop